[Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck].
Serum concentrations of Cyfra 21-1, a soluble cytokeratin fragment, were evaluated in 157 healthy patients, 66 patients with benign ear, nose or throat disease, and 102 patients with untreated epidermoid carcinoma of the head and neck. The technique had a sensitivity of 53.9% and specificity of 98.4% for a cutoff value of 1.5 ng/ml. Cyfra 21-1 levels differed significantly with tumor location (p < 0. 005) and tumor stage (p < 0.005), but not with the degree of histological differentiation.
González Sánchez
E
E
Dpto. de ORL, Hospital Universitario de Salamanca, Salamanca, Salamanca, 37005, España.
López-Ríos Velasco
J
J
Calvo Boizas
E
E
García-Talavera Fernández
J R
JR
Martín Ro-dríguez
M
M
Muñoz Herrera
A
A
Del Cañizo Alvarez
A
A
D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000175:diagnosis*; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000175:diagnosis*; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D012680:Sensitivity and Specificity
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; C102012:antigen CYFRA21.1; D007633:Keratins